Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
Our Science
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

Presentations

Presentations

Corporate Presentations

Scientific Publications

J.P. Morgan Healthcare Conference Presentation

Jan 10, 2022

J.P. Morgan Healthcare Conference Presentation 3.2 MB

Cerevel Therapeutics Corporate Presentation

Nov 10, 2021

3Q 2021 Financial Results & Business Update 4.5 MB

Cerevel Therapeutics R&D Day Presentation

Oct 07, 2021

Cerevel Therapeutics R&D Day Presentation 3.3 MB

Cerevel Therapeutics Corporate Presentation

Aug 11, 2021

2Q 2021 Financial Results & Business Update 4.5 MB

Cerevel Therapeutics Corporate Presentation

May 17, 2021

1Q 2021 Financial Results & Business Update 4 MB

$125M Non-Dilutive Financing for Tavapadon Presentation

Apr 13, 2021

$125M Non-Dilutive Financing for Tavapadon Presentation 1.1 MB

Virtual R&D Event: Darigabat, PDE4, KORA

Jan 28, 2021

View PDF 4.4 MB

Pagination

First page
Previous page
Page 1
Current page 2

Cerevel is now part of AbbVie

Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders.

Read the press release

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- Darigabat
- CVL-231
- CVL-936
Investors & MediaInvestors & Media
- Overview
- News & Events
- Stock
- Financials
- Governance
- Resources
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy
FCOI
Early Access Program (EAP) Policy

© 2024 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.